NLRP3 and diabetes mellitus: In vivo, CORM2 treatment prevented NLRP3 activation in an experimental model of LPS-driven acute lung injury [120], while CORM-3 administration resulted in decreased IL-1β production in mice with streptozotocin-induced diabetes [121] and suppressed NLRP3 activation in cardiac fibroblasts from mice with LPS-induced sepsis resulting in improved cardiac function [122].